Advances in immune checkpoint inhibitor combination strategies for microsatellite stable colorectal cancer
J Ros, F Balconi, I Baraibar, N Saoudi Gonzalez… - Frontiers in …, 2023 - frontiersin.org
Immune checkpoint inhibitors have reshaped the prognostic of several tumor types,
including metastatic colorectal tumors with microsatellite instability (MSI). However, 90-95 …
including metastatic colorectal tumors with microsatellite instability (MSI). However, 90-95 …
Immunotherapy for microsatellite stable colorectal cancers: challenges and novel therapeutic avenues
With the development of immune checkpoint inhibitors, immunotherapy researchers have
facilitated substantial progress for patients with mismatch repair deficient/microsatellite …
facilitated substantial progress for patients with mismatch repair deficient/microsatellite …
Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 …
M Fakih, KPS Raghav, DZ Chang, T Larson… - …, 2023 - thelancet.com
Background Anti-programmed cell death protein 1 antibodies plus multikinase inhibitors
have shown encouraging activity in several tumour types, including colorectal cancer. This …
have shown encouraging activity in several tumour types, including colorectal cancer. This …
Regorafenib, ipilimumab, and nivolumab for patients with microsatellite stable colorectal cancer and disease progression with prior chemotherapy: a phase 1 …
Importance Immunotherapy combinations with activity in patients with microsatellite stable
(MSS) metastatic colorectal cancer need to be identified. Objective To determine the …
(MSS) metastatic colorectal cancer need to be identified. Objective To determine the …
Cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies: phase Ib CAMILLA trial results
This is the phase Ib part of the phase I/II CAMILLA trial evaluating cabozantinib plus
durvalumab in advanced chemo-refractory proficient mismatch repair or microsatellite stable …
durvalumab in advanced chemo-refractory proficient mismatch repair or microsatellite stable …
Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)/microsatellite stable (MSS) colorectal cancer
TA Telli, G Bregni, M Vanhooren, RS Conde… - Cancer Treatment …, 2022 - Elsevier
Immune checkpoint inhibitors (ICIs) have marked a new era of cancer treatment, showing
remarkable efficacy in a wide range of solid malignancies. In colorectal cancer (CRC) …
remarkable efficacy in a wide range of solid malignancies. In colorectal cancer (CRC) …
[HTML][HTML] Advances in immunotherapy for MMR proficient colorectal cancer
H Lote, N Starling, R Pihlak, M Gerlinger - Cancer treatment reviews, 2022 - Elsevier
Survival in mismatch-repair proficient (MMRp) metastatic colorectal cancer (mCRC) remains
poor and chemotherapy is the mainstay of treatment. Immunotherapy has demonstrated …
poor and chemotherapy is the mainstay of treatment. Immunotherapy has demonstrated …
[HTML][HTML] From Crypts to Cancer: A Holistic Perspective on Colorectal Carcinogenesis and Therapeutic Strategies
E Gharib, GA Robichaud - International journal of molecular sciences, 2024 - mdpi.com
Colorectal cancer (CRC) represents a significant global health burden, with high incidence
and mortality rates worldwide. Recent progress in research highlights the distinct clinical …
and mortality rates worldwide. Recent progress in research highlights the distinct clinical …
Current landscape and potential challenges of immune checkpoint inhibitors in microsatellite stable metastatic colorectal carcinoma
M San-Román-Gil, J Torres-Jiménez, J Pozas… - Cancers, 2023 - mdpi.com
Simple Summary The implementation of immunotherapy in the therapeutic landscape of
colorectal carcinoma has been difficult due to the inefficacy reported in early clinical trials …
colorectal carcinoma has been difficult due to the inefficacy reported in early clinical trials …
Deciphering treatment resistance in metastatic colorectal cancer: roles of drug transports, EGFR mutations, and HGF/c-MET signaling
N Albadari, Y Xie, W Li - Frontiers in Pharmacology, 2024 - frontiersin.org
In 2023, colorectal cancer (CRC) is the third most diagnosed malignancy and the third
leading cause of cancer death worldwide. At the time of the initial visit, 20% of patients …
leading cause of cancer death worldwide. At the time of the initial visit, 20% of patients …